Fundraising Fox
Antlia Bioscience, Inc.
Encinitas, US · Founded 2020 · Delaware corporation · 5 employees on LinkedIn · 1 known investors
Find your way into Antlia Bioscience, Inc.
Sign up to see every warm intro you have to Antlia Bioscience, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antlia Bioscience, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Antlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.
Founders & leadership
BL
Brian Laurence JohnsonExecutive
AM
Ankit MahadeviaNamed on SEC filing
Board
BA
Ben AuspitzBoard director
MT
NS
CG
Carlos Garcia EcheverriaBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.9M disclosed across 3 rounds · 2020–2026
▶$6MraisedJun 2026 · 3 investors · BiotechnologyRule 506(b)
▶$6MraisedJun 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ankit MahadeviaExecutive Officer, Director
- Ben AuspitzDirector
- Martin TaylorDirector
- Carlos Garcia EcheverriaDirector
- Nihal SinhaDirector
- Brian Laurence JohnsonExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $6M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$680KraisedApr 2022 · 10 investors · Other TechnologyRule 506(b)
▶$680KraisedApr 2022 · 10 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brian Laurence JohnsonExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $680K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$207KraisedOct 2020 · 7 investors · Other TechnologyRule 506(b)
▶$207KraisedOct 2020 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brian Laurence JohnsonExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $207K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Ancilia BioAncilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Intellia TherapeuticsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Revalia Bio, Inc.Revalia Bio uses AI to convert donated human organs and tissues into multi-modal biological datasets and decision-ready insights for drug and device development. It operates an Organ ICU facility and works with organ procurement organizations and healthcare institutions to serve pharma, biotech, and medical device companies.
Companies working in the same space as Antlia Bioscience, Inc..
Frequently asked questions
- What does Antlia Bioscience, Inc. do?
- Antlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.
- Who are Antlia Bioscience, Inc.'s investors?
- Antlia Bioscience, Inc.'s investors include F-Prime Capital.
- How much funding has Antlia Bioscience, Inc. raised?
- Antlia Bioscience, Inc. has disclosed $6.9M raised across 3 rounds.
- Where is Antlia Bioscience, Inc. headquartered?
- Antlia Bioscience, Inc. is headquartered in Encinitas, US.